Agenus to report fourth quarter and year end 2013 financial results on march 5, 2014; conference call to follow

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen) will release its fourth quarter and year end 2013 financial results before the market opens on march 5, 2014. agenus executives will host a conference call at 11:00 a.m. eastern time that same day. to access the live call, dial 647-426-1845. the call will also be webcast and will be accessible from the company’s website at www.agenusbio.com/webcast/. a replay will be available approximately two hours after the call through midnight eastern time on may 5, 2014. the replay number is 416-915-1035, and the access code is 498676. the replay will also be available on the company’s website approximately two hours after the live call. about agenus agenus is a biopharmaceutical company focused on immuno-oncology with a portfolio of checkpoint modulators and anti-cancer vaccines. the company’s three platforms include checkpoint modulators, heat shock protein based vaccines, and adjuvants. the company’s proprietary discovery engine retrocyte display® generates high quality therapeutic antibody drug candidates quickly using a high-throughput approach incorporating full-length igg format human antibody libraries expressed in mammalian b-lineage cells. a portfolio of checkpoint modulator programs is advancing in preclinical development, several heat shock protein vaccines are in phase 2 studies, and the qs-21 stimulon® adjuvant platform is extensively partnered with glaxosmithkline and janssen and includes several candidates in late-stage trials. among agenus and its partners, 23 programs are in clinical development. for more information, please visit www.agenusbio.com, or connect with the company on facebook, linkedin, twitter and google+.
AGEN Ratings Summary
AGEN Quant Ranking